John Smeraglia (UCB, Brussels, Belgium) explains how translational biomarkers fit into the bioanalytical landscape and how to select an appropriate analytical methodology when carrying out translational studies.
In this interview Annette Bak, Head of Advanced Drug Delivery at AstraZeneca (Sweden), discusses her passion for engaging with the scientific community and for advocating career development for women.
In this interview Sanyogitta Puri, Associate Director (AstraZeneca, Cambridge, UK), explores AstraZeneca’s involvement in the cell and gene therapy field.
Uma Kavita (Bristol-Myers Squibb, NJ, USA) discusses lipid nanoparticle drug products and explains the importance of immunogenicity assessments as well as some of the challenges with current regulatory guidance.
In this interview, Mark Bayliss (North Bristol NHS Trust, Southmead Hospital; Bristol, UK) discusses his bioanalytical career and explores the importance of bioanalysis through observations in made in his current research.
In this interview Robert Nelson, Associate Director of Science and Innovation at Covance (Geneva, Switzerland) discusses the importance of biomarkers in drug development, describing key aspects in the current guidance and key considerations to make in the development and validation process.
In this interview Ulrich Mayer, Technical Sales Specialist (Bio-Rad laboratories, CA, USA) talks about Bio-Rad’s capabilities with the generation of custom antibodies for assay development.
In this interview, Richard Kay (Wellcome Trust, University of Cambridge, UK) discusses his use of HRMS and QQQ for the analysis of the peptidome.
In this interview Joel Mathews (Ionis Pharmaceuticals Inc., CA, USA) discusses his role in the development of biomarker, PK and immunogenicity assays in the development of protein therapeutics. He explains his interest in the field and explores the use of LBA for biomarker validation